BSD sets sights on US 510(k) for MicroThermX:
This article was originally published in Clinica
Executive Summary
BSD Medical has begun preparations to gain US FDA 510(k) clearance for its MicroThermX 100 system for treating cancer via precision-guided microwave thermal ablation. The Salt Lake City, Utah company, which already sells precision-guided radiofrequency (RF) and microwave systems for use in conjunction with chemotherapy and/or radiotherapy, said that the new product is intended to broadly expand its market by also targeting cancers that can be treated by heat alone. Another of the firm's RF/microwave heating cancer treatment systems, BSD-2000, is pending premarket approval (PMA) clearance in the US.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.